Resources
7 Results (showing 1 - 7)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 7/22/2020 (updated 3/28/2024)
New York State's Opioid Overdose Prevention Program Resources
Posted 8/11/2020 (updated 3/28/2024)
Sonoran Prevention Works is an advocate for people in Arizona affected by drug use. Spanish language resources from Ssamaritan PAWZ are included.
Posted 9/22/2020 (updated 3/29/2024)
The Post-Overdose Response (PORT) Toolkit was developed as a resource for North Carolina communities who are interested in creating a post-overdose response team (PORT) in their jurisdiction.
Posted 3/25/2021 (updated 4/5/2024)
Stimulants 2021: An Update—Clinical Issues and Treatments
The presenter will review considerations in engaging and treating individuals with stimulant use disorders and present evidence-based treatment strategies relevant to rural communities addressing this growing problem.
Posted 7/7/2021 (updated 4/2/2024)
This Technical Briefing provides a description of Peer-to-Peer Distribution of Naloxone (P2PN). This is based on six case studies of pioneers of P2PN; three from the UK and three international examples that inform the guidance in this Technical Briefing. This document will inform and be extended following a pilot of P2PN in four sites in England in 2019. These will be supported by small grants from EuroNPUD. The learning from this pilot will help test the model and peer education approach promoted in this briefing.
Posted 8/19/2021 (updated 4/2/2024)
In spring 2021, pharmaceutical manufacturers and distributors notified syringe services programs (SSPs) and partners that there would be significant interruptions in the supply of injectable/intramuscular (IM) naloxone. Currently, production and distribution delays are expected to last until fall 2021. This will specifically affect SSPs because IM naloxone is the most affordable formulation, and therefore is most commonly utilized by programs that distribute large volumes of naloxone to reduce fatal overdose rates.
Posted 11/17/2021 (updated 4/3/2024)
The National Academies of Science, Engineering, and Medicine defines stigma as a range of negative attitudes, beliefs and behaviors that are associated with certain conditions such as addiction. Dr. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA), has been a leading voice in talking about the “chilling effect” stigma has on our ability to address substance use and addiction in our country. In an April 2020 perspective piece published in the New England Journal of Medicine and in her NIDA blog piece, Dr. Volkow explains how stigma can prevent people from seeking care and can even contribute to their continuing addiction. We encourage our visitors to read Dr. Volkow’s writings as well as to familiarize themselves with the efforts to reduce stigma led by the National Institutes of Health (NIH) including the NIH HEAL InitiativeSM, which has made addressing stigma a key element in their efforts to address opioid addiction.